HALO

Completed study

Official Study Title
Heparin AnticoaguLation to improve Outcomes in septic shock: The HALO international phase II RCT

Brief Description
HALO-HCA2017 is a randomized clinical trial aiming to study if heparin, a widely available, inexpensive anticoagulant, may improve clinical outcomes in patients with septic shock.

Details
Status: Completed
Study Type: Interventional (Clinical Trial)
Study phase: II
Study sites: 2 sites in Greece
Actual enrolment: 50 participants

EudraCT number: 2018-003726-93
National Organization for Medicines Approval: IS047-19
National Ethics Committee Approval: 52/19

Study Start: July 2019
Study Completion: December 2021

Condition/Disease studied: sepsis
Keywords: Heparin Anticoagulation; septic shock